Loading clinical trials...
Loading clinical trials...
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Conditions
Interventions
TRx0237
Placebo
Locations
67
United States
David Geffen School of Medicine at UCLA, UCLA Neurological Services
Los Angeles, California, United States
The Shankle Clinic
Newport Beach, California, United States
Memory and Aging Centre
San Francisco, California, United States
Meridien Research
Brooksville, Florida, United States
Mayo Clinic
Jacksonville, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Start Date
May 1, 2013
Primary Completion Date
February 1, 2016
Completion Date
February 1, 2016
Last Updated
March 14, 2018
Lead Sponsor
TauRx Therapeutics Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions